Aggressive investor
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$LPCN 4 near term catalysts by 12/31/15
1. 60 day acceptance with no ADCOM assign by FDA (wish)
2. PDUFA date established
3. Lpcn1111, once a day, phase 2b trial start
4. 1107 pre-term birth dose finding study
$LPCN 4 near term catalysts by 12/31/15
1. 60 day acceptance with no ADCOM assign by FDA (wish)
2. PDUFA date established
3. Lpcn1111, once a day, phase 2b trial start
4. 1107 pre-term birth dose finding study
$LPCN - new price target update
http://www.moneyflowindex.org/lipocine-inc-nasdaqlpcn-price-target-update/3136666/
$LPCN - new price target update
http://www.moneyflowindex.org/lipocine-inc-nasdaqlpcn-price-target-update/3136666/
$LPCN to Participate at Ladenburg Thalmann 2015 Healthcare Conference
http://www.streetreport.co/lipocine-inc-nasdaqlpcn-to-participate-at-ladenburg-thalmann-2015-healthcare-conference/23287/
$LPCN to Participate at Ladenburg Thalmann 2015 Healthcare Conference
http://www.streetreport.co/lipocine-inc-nasdaqlpcn-to-participate-at-ladenburg-thalmann-2015-healthcare-conference/23287/
$LPCN to present at Ladenburg Thalmann 2015 Healthcare Conference
http://stocknewsnow.com/companynews/78240117/LPCN/101843
$LPCN to present at Ladenburg Thalmann 2015 Healthcare Conference
http://stocknewsnow.com/companynews/78240117/LPCN/101843
Zacks Short Term Rating on $LPCN
The company has received an average rating of 1 from 4 brokerage firms. 4 analysts have rated the company as a strong buy.
http://www.insidertradingreport.org/zacks-short-term-rating-on-lipocine-inc/6106611/
Zacks Short Term Rating on $LPCN
The company has received an average rating of 1 from 4 brokerage firms. 4 analysts have rated the company as a strong buy.
http://www.insidertradingreport.org/zacks-short-term-rating-on-lipocine-inc/6106611/
$NRIFF (OTC) Announces Intention to Split Into Two Publicly Traded Companies
TSX: NRI
http://web.tmxmoney.com/article.php?newsid=78125763&qm_symbol=NRI
$NRIFF Announces Intention to Split Into Two Publicly Traded Companies
http://web.tmxmoney.com/article.php?newsid=78125763&qm_symbol=NRI
$NRIFF Announces Intention to Split Into Two Publicly Traded Companies
http://web.tmxmoney.com/article.php?newsid=78125763&qm_symbol=NRI
$LPCN would've preferred green obviously but ok close. Waiting for PDUFA announcement
$NRIFF ...Announces Intention to Split Into Two Publicly Traded Companies
http://web.tmxmoney.com/article.php?newsid=78125763&qm_symbol=NRI
$NRIFF ...Announces Intention to Split Into Two Publicly Traded Companies
http://web.tmxmoney.com/article.php?newsid=78125763&qm_symbol=NRI
$LPCN in consolidation mode
$DVAX phase 3 result in October 2015
$DVAX phase 3 result in October 2015
$IGXT current SEC filing
http://ih.advfn.com/p.php?pid=nmona&article=68473204
$IGXT current SEC filing
http://ih.advfn.com/p.php?pid=nmona&article=68473204
$IGXT: IntelGenx Corp. and RedHill Biopharma Ltd Announce Positive Outcome of the Decentralized Procedure for Approval of RIZAPORT(TM) in Europe
http://finance.yahoo.com/news/intelgenx-corp-redhill-biopharma-ltd-134700488.html
$IGXT: IntelGenx Corp. and RedHill Biopharma Ltd Announce Positive Outcome of the Decentralized Procedure for Approval of RIZAPORT(TM) in Europe
http://finance.yahoo.com/news/intelgenx-corp-redhill-biopharma-ltd-134700488.html
$LPCN - $LPCN Current price $19.00 Target mid term $36.00; Short Term: $25.00 by September 2015
Outstanding Shares: 18.20 million
Institution Hold 47 % and Insider hold 45%
Submitted NDA to FDA for a blockbuster product, one of a kind
FDA approval by first quarter 2016 (exact date to be announced hopefully by next week)
Current market cap below 400 million ( a sheer joke) entering into 2.0 billion market alone in the USA.
Always buy value, Good luck.
$LPCN Pre-market on fire on Zacks new rating...
http://www.americantradejournal.com/zacks-rating-on-lipocine-inc-nasdaqlpcn/669853/
$LPCN Pre-market on fire on Zacks new rating...
http://www.americantradejournal.com/zacks-rating-on-lipocine-inc-nasdaqlpcn/669853/
$LPCN current price 300% discount price. They have product one of a kind.
$LPCN hit new 52 weeks high
$LPCN: Fair Value $60+ up to $100+ /share for oral Testosterone when successfully launched http://finance.yahoo.com/mbview/threadview/?&/mbview/threadview/?&bn=a01e6608-f2fb-371e-a4e7-481bf9668858&tid=1437412577513-d505b347-9ba9-424e-a7ee-281fe4b653f5
$LPCN another good buying opportunity for next rise to ...
Twenty Five
Focus Ticker: $LPCN
The FDA has cautioned about the use of testosterone products for low testosterone due to aging. The agency is also concerned about safety issues. There is certainly a risk associated with existing testosterone products, which include topical gels, patches and invasives. However, many of the problems associated with existing products do not exist with LPCN 1021, which is an oral TRT.
Given that many of the problems associated with existing products do not exist with oral TRT, it is likely that the FDA might give a nod to LPCN 1021 despite it being cautious about testosterone replacement therapies. And given that an oral therapy is more convenient than topical gels and invasives, LPCN 1021 has the potential, if approved, to capture a significant portion of the $2.3 billion testosterone replacement market.
http://seekingalpha.com/article/3481346-premarket-biotech-digest-natural-killer-cells-lipocine-nda-fda-calendar
Focus Ticker: $LPCN
The FDA has cautioned about the use of testosterone products for low testosterone due to aging. The agency is also concerned about safety issues. There is certainly a risk associated with existing testosterone products, which include topical gels, patches and invasives. However, many of the problems associated with existing products do not exist with LPCN 1021, which is an oral TRT.
Given that many of the problems associated with existing products do not exist with oral TRT, it is likely that the FDA might give a nod to LPCN 1021 despite it being cautious about testosterone replacement therapies. And given that an oral therapy is more convenient than topical gels and invasives, LPCN 1021 has the potential, if approved, to capture a significant portion of the $2.3 billion testosterone replacement market.
http://seekingalpha.com/article/3481346-premarket-biotech-digest-natural-killer-cells-lipocine-nda-fda-calendar
$LPCN is acting great, up on Wednesday 1.34 to 16.93, or 8.6%. Since June, the base pattern was taken out with a thrust, they formed a flag or wedge, another explosive move took place, and then they had a sharp pullback. That held the trendline, price support, and moving averages, and came sharply off of that. It’s been up 7 consecutive days. I expect it to test 17 3/4-18, and then run with a target of 21 1/2-22 by end of Sept 2015.
$LPCN showing extreme strength
$LPCN hoping for 20 range very soon.
Thx for posting $LPCN chart. As per chart, new 52 weeks high by tomorrow
$LPCN ok I'm calling 20 by sept 14. I'm feeling real bullish with this now. Couple upgrades and lift off imo!
$LPCN ok I'm calling 20 by sept 14. I'm feeling real bullish with this now. Couple upgrades and lift off imo!
$LPCN Lipocine Inc. Analyst Rating Update
http://www.americantradejournal.com/lipocine-inc-analyst-rating-update/663398/
From Yahoo board....
http://finance.yahoo.com/mbview/threadview/?&/mbview/threadview/?&bn=a01e6608-f2fb-371e-a4e7-481bf9668858&tid=1437412577513-d505b347-9ba9-424e-a7ee-281fe4b653f5
$LPCN Lipocine Inc. Analyst Rating Update
http://www.americantradejournal.com/lipocine-inc-analyst-rating-update/663398/
From Yahoo board....
http://finance.yahoo.com/mbview/threadview/?&/mbview/threadview/?&bn=a01e6608-f2fb-371e-a4e7-481bf9668858&tid=1437412577513-d505b347-9ba9-424e-a7ee-281fe4b653f5